Compare · DXCM vs SOLY
DXCM vs SOLY
Side-by-side comparison of DexCom Inc. (DXCM) and Soliton, Inc. (SOLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SOLY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $30.78B.
- DXCM has hit the wire 15 times in the past 4 weeks while SOLY has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for SOLY).
- Company
- DexCom Inc.
- Soliton, Inc.
- Price
- -
- -
- Market cap
- $30.78B
- -
- 1M return
- -3.77%
- -
- 1Y return
- +38.15%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2019
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Soliton, Inc.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas.
Latest DXCM
- Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
- EVP Chief Legal Compliance Off Michael Jon Brown sold $141,882 worth of shares (1,700 units at $83.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 95,034 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Latest SOLY
- SEC Form 15-12B filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form SC 13D/A filed by Soliton, Inc. (Amendment)
- SEC Form 4: Remeditex Ventures Llc returned $208,242,660 worth of shares to the company (9,214,277 units at $22.60)
- SEC Form 4: Tanner Joe D returned $1,808,000 worth of shares to the company (80,000 units at $22.60), closing all direct ownership in the company
- SEC Form 4: Klemp Walter V returned $9,605,000 worth of shares to the company (425,000 units at $22.60), closing all direct ownership in the company
- SEC Form 4 filed by Kaminer Michael S.
- SEC Form 4 filed by Hunt Niquette L.